# Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

> **NCT01617629** · PHASE2 · COMPLETED · sponsor: **Prima BioMed Ltd** · enrollment: 9 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **BIOLOGICAL:** MUC1 Dendritic Cell Vaccine (Cvac)

## Key facts

- **NCT ID:** NCT01617629
- **Lead sponsor:** Prima BioMed Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617629, "Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01617629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*